Sentences with phrase «pembrolizumab in»

The phase II part of a phase Ib / II study (ClinicalTrials.gov identifier: NCT02263508; MASTERKEY - 265)[24] assessing the safety and efficacy of T - VEC in combination with the PD - 1 — blocking antibody pembrolizumab in previously untreated, unresected stage IIIB / IV melanoma is evaluating confirmed ORR by irRECIST at week 24.

Tanguy Seiwert, M.D., of The University of Chicago, presented results of a phase 1b trial of Merck's pembrolizumab in a cohort of patients with advanced head and neck cancer.

The KEYNOTE - 183, KEYNOTE - 185, and KEYNOTE - 023 trials evaluating the programmed death 1 (PD - 1) inhibitor pembrolizumab in combination with pomalidomide or lenalidomide for patients with multiple myeloma were placed on hold due to the increase in deaths on the pembrolizumab arms of KEYNOTE - 183 and KEYNOTE - 185 trials.

Mehnert JM, Panda A, Zhong H, Hirshfield K, Damare S, Lane K, Sokol L, Stein MN, Rodriguez - Rodriquez L, Kaufman HL, Ali S, Ross JS, Pavlick DC, Bhanot G, White EP, DiPaola RS, Lovell A, Cheng J, Ganesan S. Immune activation and response to pembrolizumab in POLE - mutant endometrial cancer.

Naiyer Rizvi, M.D., of Memorial Sloan Kettering, presented results of pembrolizumab in lung cancer.

A Phase 1b / 2 Open - label Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer With Expansion Cohorts in Patients With Non-small Cell Lung Cancer and Melanoma

In fact, the Food and Drug Administration's approval of pembrolizumab in May 2017 for adult and pediatric patients with solid tumors and high microsatellite instability, was the first time it had approved a cancer treatment based on a genetic feature rather than the cancer's location of origin.

A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO - 2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic Melanoma

Its first test: CMP - 001 and pembrolizumab in melanoma patients who are failing treatment with pembrolizumab.

Alley said there are already plans for trials that will test combination therapies, which will utilize pembrolizumab in conjunction with other treatments.

But here Butler and colleagues pull three trials together and show that long - lasting responses also occur with pembrolizumab in patients with mucosal melanoma.»

Not exact matches

Treating patients with an antibody called pembrolizumab (sold under the brand name Keytruda) caused these T cells to increase in number, says coauthor Kellie Smith, a cancer immunologist at Johns Hopkins University.

Researchers are currently testing pembrolizumab to determine if it has the same result in other cancers, as well as trying to combine pembrolizumab with other therapies.

The idea to specifically study this group of patients was based on groundbreaking research Garon published in the New England Journal of Medicine last year, which found that among patients who received pembrolizumab, those with PD - L1 expression on at least 50 percent of their cancer cells showed the longest survival and disease control.

Dr. Glen Weiss, M.D., M.B.A., is the first author of the study abstract: Phase Ib / II Study of Pembrolizumab plus Chemotherapy in Advanced Cancer: Results of lung cancer patients receiving (at least) 1 prior line of therapy.

Pembrolizumab, or pembro, an immunotherapy drug that unmasks cancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona.

We are currently waiting for the results of several trials including EORTC 1325 which is investigating pembrolizumab, a PD - 1 checkpoint blocking antibody, compared to placebo in the adjuvant setting.»

Response rates, overall survival and progression - free survival rates were superior in the pembrolizumab and chemotherapy combination - treatment group.

In a phase 1b clinical trial with 21 patients, researchers tested the safety and efficacy of combining the immunotherapy drug pembrolizumab with an oncolytic virus called T - VEC.

Patients in the chemotherapy arm who progressed were eligible to crossover to pembrolizumab as second line treatment — this occurred in 44 % of these patients.

In Cohort A, pembrolizumab shrunk tumors by more than 30 percent in eight of 170 patients, or five percent, and stabilized the disease in 35, or 21 percent, of those previously treated for mTNBIn Cohort A, pembrolizumab shrunk tumors by more than 30 percent in eight of 170 patients, or five percent, and stabilized the disease in 35, or 21 percent, of those previously treated for mTNBin eight of 170 patients, or five percent, and stabilized the disease in 35, or 21 percent, of those previously treated for mTNBin 35, or 21 percent, of those previously treated for mTNBC.

The immunotherapy drug pembrolizumab — already FDA - approved for other forms of cancer - has been found to be effective in patients with metastatic triple negative breast cancer, according to an international clinical trial led by NYU Langone's Perlmutter Cancer Center.

By injecting T - VEC into the patients» tumors, even those that were located deeper in the body, the researchers were able to transform cold tumors into hot ones, which in turn allowed pembrolizumab to deliver a beneficial enhancement.

«Interestingly, we found that activity of pembrolizumab was seen in both PD - L1 - positive and - negative tumors.

Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD - L1 expression, according to the results of the phase III KEYNOTE - 024 trial presented at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine.

In Cohort B — those who received pembrolizumab as first - line therapy — 12 of 52 patients, or 23 percent, saw tumors shrink by more than 30 percent, while the disease was stabilized in nine of them, or 17 percenIn Cohort B — those who received pembrolizumab as first - line therapy — 12 of 52 patients, or 23 percent, saw tumors shrink by more than 30 percent, while the disease was stabilized in nine of them, or 17 percenin nine of them, or 17 percent.

Drugs like pembrolizumab boost the response in tumors where immune cells are present but don't work in tumors where there is no immune response to boost.

«The reason KEYNOTE - 024 met its primary endpoint, in contrast with other studies, is probably because the trial only included patients who had PD - L1 expression of at least 50 % and were therefore optimal candidates for treatment with pembrolizumab,» he added.

«The significant improvement in overall survival with pembrolizumab was remarkable given that more than 40 % of patients crossed over from the control arm to pembrolizumab after progression of the disease,» said Reck.

KEYNOTE - 024 investigated the efficacy of pembrolizumab compared to standard of care with platinum - based chemotherapy in untreated patients with advanced NSCLC and high PD - L1 expression (defined as expression in at least 50 % of tumour cells).

In addition to helping patients live longer, more patients treated with pembrolizumab responded to treatment and for a longer duration than those treated with chemotherapy; the objective response rate — the percentage of patients whose tumours shrank or disappeared — was almost twice as high with pembrolizumab: 21 % compared to 11 % on chemotherapy.

Reporting the results from three trials of pembrolizumab for patients with advanced melanoma, Dr Marcus Butler, a medical oncologist at the Princess Margaret Cancer Centre, Toronto, Canada, told ECCO2017 that 84 of the 1567 patients in the KEYNOTE - 001, 002 and 006 studies had advanced mucosal melanoma.

It represents a real advance in the second - line treatment of advanced bladder cancer because pembrolizumab is the first therapy to show a significant survival advantage over chemotherapy for these patients.

«In addition to the overall survival benefit over chemotherapy, pembrolizumab was also associated with a much lower incidence of treatment - related side effects.

Patients in the KEYNOTE trials received pembrolizumab intravenously at doses of 2 mg / kg or 10 mg / kg every three weeks, or 10 mg / kg every two weeks.

In 2017, the U.S. Food and Drug Administration (FDA) approved the cancer drug Keytruda (pembrolizumab) for a range of solid tumors that are either microsatellite instability - high (MSI - H) or mismatch repair deficient (dMMR).

Alley and his team presented data from KEYNOTE - 028, an ongoing trial involving 13 different research sites in six different countries all looking at the effect of pembrolizumab on patients with advanced malignancies, including malignant pleural mesothelioma.

The immunotherapy drug pembrolizumab, when combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer (NSNSCLC) lacking genetic changes in the EGFR or ALK genes, when compared to...

«Pembrolizumab shows promise in treatment of mesothelioma.»

Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the University of Pennsylvania.

Pembrolizumab, in particular, has been used to treat melanoma, non-small cell lung cancer, and in some cases, head and neck cancers.

Phase I Study of MK - 3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed / Refractory or Disseminated Malignant Neoplasm

On October 2, 2015, the FDA approved the immunotherapy drug pembrolizumab (Keytruda ®), made by Merck, as second - line treatment for patients with lung cancer, the leading cause of cancer - related death in the U.S. and the world.

A Randomized, Double - Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First - line Chemotherapy in Patients with Metastatic Urothelial Cancer

A Phase I / II Study of Pembrolizumab (MK - 3475) in Children with Advanced Melanoma or a PD - L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma

Aside from atezolizumab, immunotherapies in this class include avelumab (Bavencio); pembrolizumab (Keytruda); and nivolumab (Opdivo).

In melanoma patients who are also treated with the immune therapy pembrolizumab after surgery, the risk of recurrence of the disease is almost twice as small as in patients who receive a placebIn melanoma patients who are also treated with the immune therapy pembrolizumab after surgery, the risk of recurrence of the disease is almost twice as small as in patients who receive a placebin patients who receive a placebo.

The immunotherapy pembrolizumab was active in patients with advanced mucosal melanoma enrolled in a series of the KEYNOTE clinical trials, according to data presented at the European Cancer Congress 2017.

Zakharia, who presented the data at the 2017 American Association for Cancer Research (AACR) Annual Meeting in Washington, DC, reveals the overall response data from the trial, toxicity data, and compares the results to historical data of pembrolizumab monotherapy from KEYNOTE - 006, which included similar patients.

Pembrolizumab (Keytruda) and nivolumab (Opdivo)-- two checkpoint inhibitors that target the PD - 1 pathway — received FDA approval in 2014 for melanoma that did not respond to prior treatment.